Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $573.7 million.

  • Kymera Therapeutics' Non-Current Assets rose 23.09% to $573.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $573.7 million, marking a year-over-year increase of 23.09%. This contributed to the annual value of $467.8 million for FY2024, which is 174.44% up from last year.
  • Kymera Therapeutics' Non-Current Assets amounted to $573.7 million in Q3 2025, which was up 42.46% from $402.7 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Non-Current Assets peaked at $573.7 million during Q3 2025, and registered a low of $69.6 million during Q2 2021.
  • For the 3-year period, Kymera Therapeutics' Non-Current Assets averaged around $336.9 million, with its median value being $331.0 million (2024).
  • Per our database at Business Quant, Kymera Therapeutics' Non-Current Assets plummeted by 52.99% in 2021 and then soared by 174.44% in 2024.
  • Kymera Therapeutics' Non-Current Assets (Quarterly) stood at $154.6 million in 2021, then grew by 18.81% to $183.7 million in 2022, then decreased by 7.23% to $170.4 million in 2023, then spiked by 174.44% to $467.8 million in 2024, then rose by 23.09% to $573.7 million in 2025.
  • Its Non-Current Assets stands at $573.7 million for Q3 2025, versus $402.7 million for Q2 2025 and $417.4 million for Q1 2025.